Lilly(US:LLY) GLP1减重宝典·2025-09-06 03:53Core Viewpoint - The recent submission of Eli Lilly's drug "Tirzepatide Injection" for inclusion in the 2025 National Medical Insurance Directory has garnered significant attention in the industry [2]. Group 1: Drug Approval and Market Context - Tirzepatide is a dual agonist that acts on both GIP and GLP-1 receptors, approved in mainland China in May 2024 for treating adult Type 2 Diabetes Mellitus (T2DM) and moderate to severe obstructive sleep apnea (OSA) associated with obesity [5]. - Currently, there are seven GLP-1 receptor agonists included in the National Medical Insurance Directory, such as Exenatide, Liraglutide, and Semaglutide [5]. Group 2: Clinical Trial Results - Eli Lilly provided multiple clinical trial results indicating that Tirzepatide outperforms existing GLP-1 receptor agonists in terms of glucose reduction and weight loss. For instance, a network meta-analysis showed that Tirzepatide 5mg reduces HbA1c by 1.25% more than Semaglutide 1mg [5]. - In a randomized controlled trial, patients treated with Tirzepatide 5mg lost an average of 5kg over 40 weeks, while the weight loss in the Semaglutide 1mg group was comparatively smaller [7]. - In a Phase III study for OSA, Tirzepatide significantly reduced the Apnea-Hypopnea Index (AHI), with 51.5% of patients achieving symptom relief or mild symptom levels [7].